173 related articles for article (PubMed ID: 36601880)
1. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
3. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
4. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
5. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
7. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
[TBL] [Abstract][Full Text] [Related]
11. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
Du F; Liu Y
J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
15. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory receptor CD94/NKG2A on CD8
Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
[TBL] [Abstract][Full Text] [Related]
18.
Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
[TBL] [Abstract][Full Text] [Related]
19. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
20. Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.
Narayanan S; Kawaguchi T; Peng X; Qi Q; Liu S; Yan L; Takabe K
Sci Rep; 2019 Sep; 9(1):13455. PubMed ID: 31530839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]